122 related articles for article (PubMed ID: 19727917)
1. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine.
Lateef A; Tan KB; Lau TC
Clin Rheumatol; 2009 Dec; 28(12):1449-52. PubMed ID: 19727917
[TBL] [Abstract][Full Text] [Related]
2. Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Tsurane K; Kaneko K; Yoshida K; Tanaka R; Sago H; Murashima A
Mod Rheumatol Case Rep; 2023 Jun; 7(2):373-377. PubMed ID: 36420890
[TBL] [Abstract][Full Text] [Related]
3. Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis.
Chowdhury TA; Talib KA; Patricia J; Nye KD; Moosa SA
Cureus; 2021 Jun; 13(6):e15921. PubMed ID: 34336425
[TBL] [Abstract][Full Text] [Related]
4. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of acute generalized exanthematous pustulosis caused by hydroxychloroquine in rheumatology patients and exploration of
Luo F; Yuan XM; Xiong H; Yang YZ; Chen CM; Ma WK; Yao XM
Front Med (Lausanne); 2023; 10():1161837. PubMed ID: 37089611
[TBL] [Abstract][Full Text] [Related]
6. Severe acute generalized exanthematous pustulosis with toxic epidermal necrolysis-like desquamation: A case series of 8 patients.
Huang S; Ahmed A; Hsu S; Lee J; Motaparthi K
JAAD Case Rep; 2021 Sep; 15():115-122. PubMed ID: 34466647
[No Abstract] [Full Text] [Related]
7. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse drug reactions.
Teo YX; Walsh SA
Clin Med (Lond); 2016 Feb; 16(1):79-83. PubMed ID: 26833523
[TBL] [Abstract][Full Text] [Related]
9. Etoricoxib Induced Toxic Epidermal Necrolysis in a case of Systemic Lupus Erythematosus: A Case Report.
Pandey A; Parajuli S; Dhungel A; Devkota R; Dongol A
JNMA J Nepal Med Assoc; 2022 Sep; 60(253):811-814. PubMed ID: 36705131
[TBL] [Abstract][Full Text] [Related]
10. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus.
Paredes-Ruiz D; Martin-Iglesias D; Ruiz-Irastorza G
Expert Rev Clin Immunol; 2024 Apr; 20(4):359-373. PubMed ID: 38112074
[TBL] [Abstract][Full Text] [Related]
11. Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review.
Al Rajaibi R; Al Rumhi T; Al Abri AM
Sultan Qaboos Univ Med J; 2021 Aug; 21(3):491-494. PubMed ID: 34522420
[TBL] [Abstract][Full Text] [Related]
12. A case of recalcitrant acute generalized exanthematous pustulosis with Sjogren's syndrome: Successfully treated with low-dose cyclosporine.
İslamoğlu ZGK; Karabağli P
Clin Case Rep; 2019 Sep; 7(9):1721-1724. PubMed ID: 31534735
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Dilemma of Widespread Vesiculobullous Lesions: A Case Report.
Khadka N; Shakya S; Khatiwada D; Budhathoki P; Bhattarai TR
JNMA J Nepal Med Assoc; 2022 Jan; 60(245):86-89. PubMed ID: 35199670
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
15. Highlighting adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: A case series from a tertiary specialised burns centre.
Kherlopian A; Mewton E; Fong G; Fischer G
Australas J Dermatol; 2022 Nov; 63(4):497-504. PubMed ID: 35988137
[TBL] [Abstract][Full Text] [Related]
16. Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case.
Atak MF; Farabi B; Akbayrak A; Kalelioğlu MB; Rao BK
J Cosmet Dermatol; 2021 Aug; 20(8):2387-2389. PubMed ID: 34139069
[No Abstract] [Full Text] [Related]
17. Ethical considerations in the management of drug severe cutaneous adverse reactions.
Buckey TM; Ferreira AL; Grant-Kels JM
J Am Acad Dermatol; 2024 Jan; ():. PubMed ID: 38224911
[No Abstract] [Full Text] [Related]
18. A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine-Literature review.
Mohaghegh F; Jelvan M; Rajabi P
Clin Case Rep; 2018 Dec; 6(12):2391-2395. PubMed ID: 30564334
[TBL] [Abstract][Full Text] [Related]
19. Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.
Vallejo-Yagüe E; Martinez-De la Torre A; Mohamad OS; Sabu S; Burden AM
J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054090
[TBL] [Abstract][Full Text] [Related]
20. Toxic epidermal necrolysis-like lupus.
Roberts EJ; Melchionda V; Saldanha G; Shaffu S; Royle J; Harman KE
Clin Exp Dermatol; 2021 Oct; 46(7):1299-1303. PubMed ID: 33760256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
